Product Name	:	Mubritinib
Synonyms	:	Mubritinib; TAK 165; TAK-165
Cat No.	:	M18478
CAS Number	:	366017-09-6
Molecular Formula	:	C25H23F3N4O2
Formula Weight	:	468.47
Chemical Name	:	(E)-4-((4-(4-(1H-1,2,3-triazol-1-yl)butyl)phenoxy)methyl)-2-(4-(trifluoromethyl)styryl)oxazole
Description	:	Mubritinib, also known as TAK-165, is a protein kinase inhibitor which was under development by Takeda for the treatment of cancer. It completed phase I clinical trials (may be discontinued since 2008). Mubritinib(TAK 165) is a potent EGFR, HER2 and p34cdc2 inhibitor with IC50 of 6 nM and 0.2 μM, respectively. Mubritinib(TAK 165) also inhibits p33cdk2 and p33cdk5. Mubritinib(TAK 165) displays > 4000-fold selectivity over EGFR, FGFR, PDGFR, JAK1 and Src. Mubritinib(TAK 165) exhibits potent antiproliferative effects in ErbB2-overexpressing cancer cell lines (IC50 = 5 nM in BT474 breast cancer cells) and significantly inhibits bladder, breast and prostate cancer xenograft growth in vivo.
Pathway	:	Membrane Transporter/Ion Channel
Target	:	TRP/TRPV Channel
Receptor	:	EGFR; HER2/ErbB2; FGFR; JAK1; PDGFR
Solubility	:	DMSO : 50 mg/mL 106.73 mM; H2O : < 0.1 mg/mL
SMILES	:	c1cc(ccc1CCCCn1ccnn1)OCc1coc(n1)/C=C/c1ccc(cc1)C(F)(F)F
Storage	:	(-20℃)
Stability	:	≥ 2 years
Reference	:	



1. Nagasawa J, et al. Int J Urol, 2006, 13(5), 587-592.